豚の呼吸器系疾患治療の世界市場－成長、将来展望、競合分析（2022年～2030年）

世界の豚の呼吸器系疾患治療の市場規模は、2022年から2030年の予測期間中に7％のCAGRで成長すると予想されています。政府機関による動物疾患の治療への投資増、豚肉の消費量の増加は、市場の成長を促進しています。しかし、豚の自然防衛能力は、市場の成長を抑制しています。

当レポートでは、世界の豚の呼吸器系疾患治療市場について調査分析し、市場力学、市場分析、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 序文

• レポートの説明
  • レポートの目的
  • 対象者
  • 主な製品
• 市場セグメンテーション
• 調査手法
  • フェーズⅠ－2次調査
  • フェーズⅡ－1次調査
  • フェーズⅢ－専門家による審査
  • 仮定
  • 採用されたアプローチ

第2章 エグゼクティブサマリー

• 市場スナップショット：世界の豚の呼吸器系疾患治療市場
• 世界の豚の呼吸器系疾患治療市場（100万米ドル）（2021年）：原因物質別
• 世界の豚の呼吸器系疾患治療市場（100万米ドル）（2021年）：治療別
• 世界の豚の呼吸器系疾患治療市場（100万米ドル）（2021年）：投与経路別
• 世界の豚の呼吸器系疾患治療市場（100万米ドル）（2021年）：流通チャネル別
• 世界の豚の呼吸器系疾患治療市場（100万米ドル）：地域別
• 魅力的な投資提案（2021年）：地域別

第3章 豚の呼吸器系疾患治療市場：競合分析

• 主要な豚の呼吸器系疾患治療市場ベンダーの市場ポジショニング
• 豚の呼吸器系疾患治療市場のベンダーが採用する戦略
• 主要な業界戦略
• 階層分析：2021年と2030年の比較

第4章 豚の呼吸器系疾患治療市場：マクロ分析と市場力学

• イントロダクション
• 世界の豚の呼吸器系疾患治療市場金額（100万米ドル）（2020年～2030年）
• 市場力学
  • 市場促進要因
  • 市場抑制要因
  • 主な課題
  • 主な機会
• 促進要因と抑制要因の影響分析
• シーソー分析

第5章 豚の呼吸器系疾患治療市場、米ドル（100万）（2020年～2030年）：原因物質別

• 市場概要
• 成長と収益分析：：2021年と2030年の比較
• 市場セグメンテーション
  • ウイルス
  • マイコプラズマ
  • 細菌
  • その他

第6章 豚の呼吸器系疾患治療市場、米ドル（100万）（2020年～2030年）：治療別

• 市場概要
• 成長と収益分析：：2021年と2030年の比較
• 市場セグメンテーション
  • 薬剤
  • ワクチン
  • 類似物
  • その他

第7章 豚の呼吸器系疾患治療市場、米ドル（100万）（2020年～2030年）：投与経路別

• 市場概要
• 成長と収益分析：：2021年と2030年の比較
• 市場セグメンテーション
  • 経口
  • 非経口

第8章 豚の呼吸器系疾患治療市場、米ドル（100万）（2020年～2030年）：流通チャネル別

• 市場概要
• 成長と収益分析：：2021年と2030年の比較
• 市場セグメンテーション
  • 動物病院
  • 動物クリニック
  • 薬局
  • その他

第9章 北米の豚の呼吸器系疾患治療市場、米ドル（100万）（2020年～2030年）

第10章 英国および欧州連合の豚の呼吸器系疾患治療市場、米ドル（100万）（2020年～2030年）

第11章 アジア太平洋地域の豚の呼吸器系疾患治療市場、米ドル（100万）（2020年～2030年）

第12章 ラテンアメリカの豚の呼吸器系疾患治療市場、米ドル（100万）（2020年～2030年）

第13章 中東およびアフリカの豚の呼吸器系疾患治療市場、米ドル（100万）（2020年～2030年）

第14章 企業プロファイル

• Zoetis, Inc.
• Merck Animal Health
• Bayer AG
• Boehringer Ingelheim Vetmedica, Inc.
• Elanco Animal Health
• Virbac Group
• Norbrook
• CevaSanteAnimale
• Vetoquinol
• Bimeda holdings PLC
• Agrilabs, Inc.

List of Tables

• TABLE 1 Global Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 2 Global Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 3 Global Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 4 Global Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 5 Global Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 6 North America Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 7 North America Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 8 North America Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 9 North America Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 10 North America Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 11 U.S. Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 12 U.S. Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 13 U.S. Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 14 U.S. Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 15 U.S. Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 16 Canada Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 17 Canada Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 18 Canada Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 19 Canada Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 20 Canada Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 21 Rest of North America Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 22 Rest of North America Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 23 Rest of North America Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 24 Rest of North America Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 25 Rest of North America Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 26 UK and European Union Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 27 UK and European Union Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 28 UK and European Union Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 29 UK and European Union Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 30 UK and European Union Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 31 UK Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 32 UK Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 33 UK Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 34 UK Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 35 UK Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 36 Germany Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 37 Germany Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 38 Germany Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 39 Germany Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 40 Germany Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 41 Spain Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 42 Spain Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 43 Spain Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 44 Spain Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 45 Spain Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 46 Italy Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 47 Italy Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 48 Italy Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 49 Italy Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 50 Italy Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 51 France Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 52 France Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 53 France Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 54 France Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 55 France Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 56 Rest of Europe Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 57 Rest of Europe Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 58 Rest of Europe Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 59 Rest of Europe Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 60 Rest of Europe Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 61 Asia Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 62 Asia Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 63 Asia Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 64 Asia Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 65 Asia Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 66 China Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 67 China Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 68 China Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 69 China Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 70 China Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 71 Japan Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 72 Japan Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 73 Japan Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 74 Japan Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 75 Japan Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 76 India Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 77 India Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 78 India Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 79 India Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 80 India Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 81 Australia Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 82 Australia Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 83 Australia Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 84 Australia Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 85 Australia Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 86 South Korea Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 87 South Korea Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 88 South Korea Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 89 South Korea Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 90 South Korea Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 91 Latin America Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 92 Latin America Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 93 Latin America Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 94 Latin America Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 95 Latin America Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 96 Brazil Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 97 Brazil Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 98 Brazil Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 99 Brazil Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 100 Brazil Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 101 Mexico Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 102 Mexico Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 103 Mexico Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 104 Mexico Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 105 Mexico Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 106 Rest of Latin America Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 107 Rest of Latin America Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 108 Rest of Latin America Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 109 Rest of Latin America Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 110 Rest of Latin America Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 111 Middle East and Africa Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 112 Middle East and Africa Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 113 Middle East and Africa Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 114 Middle East and Africa Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 115 Middle East and Africa Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 116 GCC Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 117 GCC Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 118 GCC Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 119 GCC Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 120 GCC Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 121 Africa Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 122 Africa Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 123 Africa Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 124 Africa Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 125 Africa Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)
• TABLE 126 Rest of Middle East and Africa Swine Respiratory Diseases Treatment Market By Causative agent, 2020-2030, USD (Million)
• TABLE 127 Rest of Middle East and Africa Swine Respiratory Diseases Treatment Market By Treatment, 2020-2030, USD (Million)
• TABLE 128 Rest of Middle East and Africa Swine Respiratory Diseases Treatment Market By Drugs, 2020-2030, USD (Million)
• TABLE 129 Rest of Middle East and Africa Swine Respiratory Diseases Treatment Market By Route Of Administration, 2020-2030, USD (Million)
• TABLE 130 Rest of Middle East and Africa Swine Respiratory Diseases Treatment Market By Distribution Channel, 2020-2030, USD (Million)

List of Figures

• FIG. 1 Global Swine Respiratory Diseases Treatment Market: Market Coverage
• FIG. 2 Research Methodology and Data Sources
• FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
• FIG. 4 Global Swine Respiratory Diseases Treatment Market: Quality Assurance
• FIG. 5 Global Swine Respiratory Diseases Treatment Market, By Causative agent, 2021
• FIG. 6 Global Swine Respiratory Diseases Treatment Market, By Treatment, 2021
• FIG. 7 Global Swine Respiratory Diseases Treatment Market, By Route Of Administration, 2021
• FIG. 8 Global Swine Respiratory Diseases Treatment Market, By Distribution Channel, 2021
• FIG. 9 Global Swine Respiratory Diseases Treatment Market, By Geography, 2021
• FIG. 10 Market Geographical Opportunity Matrix - Global Swine Respiratory Diseases Treatment Market, 2021
• FIG. 11 Market Positioning of Key Swine Respiratory Diseases Treatment Market Players, 2021
• FIG. 12 Global Swine Respiratory Diseases Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
• FIG. 13 Global Swine Respiratory Diseases Treatment Market, By Causative agent, 2021 Vs 2030, %
• FIG. 14 Global Swine Respiratory Diseases Treatment Market, By Treatment, 2021 Vs 2030, %
• FIG. 15 Global Swine Respiratory Diseases Treatment Market, By Route Of Administration, 2021 Vs 2030, %
• FIG. 16 Global Swine Respiratory Diseases Treatment Market, By Distribution Channel, 2021 Vs 2030, %
• FIG. 17 U.S. Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030
• FIG. 18 Canada Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030
• FIG. 19 Rest of North America Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030
• FIG. 20 UK Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030
• FIG. 21 Germany Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030
• FIG. 22 Spain Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030
• FIG. 23 Italy Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030
• FIG. 24 France Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030
• FIG. 25 Rest of Europe Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030
• FIG. 26 China Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030
• FIG. 27 Japan Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030
• FIG. 28 India Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030
• FIG. 29 Australia Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030
• FIG. 30 South Korea Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030
• FIG. 31 Rest of Asia Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030
• FIG. 32 Brazil Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030
• FIG. 33 Mexico Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030
• FIG. 34 Rest of Latin America Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030
• FIG. 35 GCC Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030
• FIG. 36 Africa Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030
• FIG. 37 Rest of Middle East and Africa Swine Respiratory Diseases Treatment Market (US$ Million), 2020 - 2030

The market for swine respiratory diseases treatment market is expected to grow at a CAGR of 7% during the forecast period of 2022 to 2030. It is generally accepted that pigs are the source of the infection which is referred to as swine respiratory disease. Some of its symptoms include a sore throat, fever, body aches, and various other symptoms. These symptoms are brought on as a result of the infection agents including mycoplasma hyopneumoniae and bordetellabronchiseptica as well as viral agents such as the respiratory syndrome (PRRS) virus. Other symptoms are brought on as a result of various other symptoms.

Swine Respiratory Diseases Treatment Market

Pigs suffering from respiratory diseases have been the source of a significant amount of mortality as well as a financial burden for the swine industry. Swine respiratory infections, in particular, involve various infectious agents and have been one of the primary reasons for death in nursery pigs. Numerous preventative efforts, most notably the All-In-All-Out (AIAO) swine production system in the United States, have fallen short of meeting the aspirations of the swine sector with regard to profitability. Because of this, research on the aetiology of pneumonic swine's lungs has been given a boost, with mycoplasma hyopneumoniae being identified as the primary agent.

Additionally, in the next years, an increase in the investments made by government agencies for the treatment of veterinary diseases would further present prospective prospects for the expansion of the market for swine respiratory disease treatment. However, in the near future, the ability of pigs to naturally defend themselves against numerous pathogens might be an additional obstacle to the expansion of the market for swine respiratory illness treatments.

Rise In Consumption Of Pork Promotes Growth Of Swine Respiratory Diseases Treatment Market

The rise in the consumption of pork and the expansion of the pork industry are both major factors that are projected to promote the growth of the market for swine respiratory diseases treatment market. Also, the rapidly shifting patterns of disease are also projected to be a driving force behind the expansion of the market for the treatment of swine respiratory infections. It is expected that the increasing number of technological advancements associated with the production of pharmaceuticals would act as a further cushion for the expansion of the swine respiratory diseases treatment market. On the other hand, an increase in the choice of vegetarian food due to the risk of obesity is further predicted to restrict the expansion of the swine respiratory diseases treatment market during the course of the time period.

Investment In Large Pig Farms Will Increase Demand For Vaccines To Treat Swine Respiratory Diseases

Because of the increased amount of pork that is being produced, the market for treating swine respiratory illnesses is dominated by North America. Furthermore, pork farms are utilising vaccines as the pork sector is looking forward to producing pork that is disease free. This will further drive the growth of the swine respiratory diseases treatment market in the region throughout the time period that is being forecasted. It is anticipated that the market for the treatment of swine respiratory disorders will experience a substantial level of growth in Asia-Pacific as a result of an increase in the amount of investment that the government is making in the pig sector in order to promote large pig farms. In addition, it is projected that the rise in the expansion of the animal sector, which employs millions of people, would further fuel the growth of the swine respiratory diseases treatment market in the region in the years to come.

Spread Of Porcine Reproductive And Respiratory Syndrome Will Increase Market Growth Of Drugs For Treatment

Porcine Reproductive and Respiratory Syndrome (PRRS), which is one of the most prevalent diseases, primarily affects pigs' respiratory systems and is one of the most common respiratory disorders. A virus is responsible for causing Porcine Respiratory and Reproductive Syndrome, and this virus falls under the category of arterivirus. The condition known as PRRS is also referred to as blue-ear pig sickness. The Porcine Reproductive and Respiratory Syndrome (PRRS), commonly known as the mysterious swine sickness, was discovered in the United States in the 1980s. The PRRS disease is fast spreading throughout all of the countries that are involved in the production of pigs; at this point, there are only a very small number of countries that are PRRS-free. The consumption of pork is growing over the years in every location, which immediately encourages the pork industry to produce more pork that is free of disease. This increases the pork industry's capacity to satisfy the growing demand for pork on the worldwide market.

Production Of Pork In North America Is Increasing

The production of pork in North America is increasing as a direct response to the growing demand for pork in nations like the United States and Canada. Pork, which is free of pathogens is making a direct contribution to meeting the demand in the meat business. The vast majority of pig farms in the pork industry in North America, particularly in the United States, are now using vaccines. This is because the pork industry is working towards the goal of producing meat that is disease free. The primary purpose of vaccination is to act as a preventative measure against the infection caused by dangerous pathogens. It is becoming more common practice to administer vaccinations against porcine reproductive and respiratory syndrome (PRRS) and mycoplasma. The vaccine is administered directly to breeding females in order to ensure that the offspring are free of pathogens. Because of rising rates of vaccination, the market in North America is expected to be a large and dominant market. In addition, the market is fairly favorable for investors in the animal healthcare sector.

Increased Investment In The Research For Effective Treatment Of Swine Respiratory Diseases

Research into the etiology of porcine reproductive and respiratory illness has been sponsored by a number of pharmaceutical corporations. The treatment of swine respiratory infections has been given a significant boost as a result of this. They appear to be focusing more and more on infectious disorders, which has resulted in an expansion of our understanding of main respiratory infectious agents, which include viruses in addition to bacteria.

Research on pigs' defense systems has been sparked as a result of growing awareness about the health of pigs among pork consumers. This has, in turn, encouraged the expansion of the market for treatments for respiratory disorders in pigs. The pig reproductive and respiratory syndrome virus (PRRSV), the swine influenza virus, and porcine circovirus type 2 are the principal pathogens that are being investigated at this time. A significant amount of research has been conducted with the goal of determining the prevalence of PRRSV in swine herds in a variety of nations. The increasing application of DNA metagenomic analysis technologies has been one factor that has contributed to the market for swine respiratory diseases therapy maintaining its rapid rate of development.

Increasing Awareness Towards Animal Healthcare Will Expand The Market

The market for the treatment of swine diseases is expected to experience substantial expansion as a result of increasing awareness regarding animal health, early disease identification, and preventative treatments. The growing incidence of diseases like swine influenza and porcine parvovirus will lead to an increase in the need for treatment of swine diseases in the global market. As a result of the preventative nature of veterinary healthcare, it is anticipated that the market for the treatment of swine diseases would experience significant growth over the course of the projected period.

The market for swine illnesses treatments across the globe is being pushed forward by reasons such as the rapidly shifting disease patterns among animals. The market for the treatment of swine diseases will expand as a result of technological advancements, as well as an increase in the manufacturing of pharmaceuticals and vaccinations.

The development in people's awareness of the importance of animal health and the increase in spending by governmental entities on veterinary care are both factors that will contribute to the expansion of the swine disease treatment market. The market for the treatment of swine diseases is expected to experience significant expansion as a result of the rising incidence of porcine diseases such as swine influenza.

Challenges To The Growth Of Swine Respiratory Disease Treatment Market

The growth of the swine disease treatment market would be hampered by factors such as the sluggish economy and rising costs associated with the storage and maintenance of vaccines. The rising popularity of vegetarian cuisine, which can be attributed to the increasing danger of obesity caused by the intake of food produced by livestock, will also slow down the expansion of the market for treatments for swine diseases.

Also, severe regulatory guidelines that restrict the use of medications in swine are expected to be a factor that slows the growth of the global swine healthcare market. For example, in April of 2016, the Center for Veterinary Medicine (CVM) division of the United States Food and Drug Administration (FDA) initiated steps to withdraw carbadox drug from use in swine due to the presence of a trace amount of carcinogenic residue in pork meat. This was done because the drug was found to cause cancer in humans.

Mycoplasma-Based Causative Agents Dominated the Market In 2021

Mycoplasma-based causative agents are projected to exhibit strong growth, with a compound annual growth rate (CAGR) of 6% during the forecast period. These agents currently hold a market share of around 35% in the overall market. Mycoplasma hyopneumoniae is the primary causative agent of enzootic pneumonia, a persistent respiratory condition that can be found in pigs. Infections brought on by M. hyopneumoniae are rather widespread in virtually all of the places in which swine production takes place. These infections result in significant economic losses as a result of higher medication consumption and decreased pig performance.

Pharmaceutical Segment Clearly Owned Over 60% of the Revenue in 2021

With a current market share of approximately 62% in 2021, the pharmaceuticals category is predicted to offer rapid growth at a CAGR of 6% by the end of the forecast period, which will bring the total market share to an all-time high. The use of antibiotics during all stages of growth improves the efficiency and effectiveness of body weight gain, lowers death rates and comorbidities, reduces the prevalence of subclinical disease, and increases the overall health of pigs.

Oral Mode of Administration Clearly Dominated the Market with Market Share of Over 85%

By the conclusion of the forecast period, oral-based modes of administration are anticipated to offer rapid growth at a CAGR of 6.3%, having a market share of approximately 85% in the global market in 2021. In most cases, medication is given to farm animals through the digestive system, often known as the oral mode of administration. To make it simpler for the animals to consume the medicine, it is typically included with their food.

Veterinary Hospitals to Dominate Among Other Channels of Distribution

Because pigs are better subjects for medical research than mice due to their size, physiology, and genetic makeup being more similar to humans, veterinary hospitals are expected to hold the highest market share value of 35.0% during the year 2021. This is due to the fact that pigs are larger than mice, which makes them easier to study.

APEJ To Dominate the Market for Swine Respiratory Disorder

It is anticipated that APEJ would dominate the market for the treatment of swine respiratory disorders. However, it is in competition with Eastern Europe, which is now in the lead in terms of CAGR during the forecasted period. One of the industries that is expanding at the quickest rate throughout the majority of Asia Pacific's nations is the animal business. It is a vital industry that is connected to millions of jobs in industries that are tied to it. On the other hand, the appearance of new animal diseases poses a risk to both the health and expansion of this sector of the economy. The APEJ market includes China's pig industry, in which the Chinese government is eager to invest and expand the pig industry by increasing support for large-scale pig farmers through the implementation of supportive policies.

US Is Expected to Command A Significant Share Of The Swine Respiratory Diseases Treatment Market

Due to the presence of a well-established swine industry as well as the rising incidence of swine infections such as Swine Enteric Coronavirus Diseases (SECD), porcine epidemic diarrhoea (PEDv), and porcine delta coronavirus (PDCoV), which cause significant morbidity and mortality, particularly in young piglets, North America is expected to dominate the market. The expansion of the market that was analyzed in the region is being jointly driven by all of these different variables.

In the market for swine healthcare, it is anticipated that the United States will have a significant portion of the market share in the North American area. The United States has been either the world's largest or second-largest exporter of pork and pig products in recent years, with exports averaging over 20% of commercial pork output in most years. As the prevalence of different diseases affecting pigs continues to rise, it is projected that there will be a greater need over time for items relating to the healthcare of pigs in order to sustain the expansion of the pig farming business. A number of the programs that are conducted by the government of the United States give money for the research and development of therapies for swine diseases. It is anticipated that this will further contribute to the expansion of the market in the United States.

Market to Remain Fragmented and Strategic Collaborations to Provide Competitive Advantage

The overall market is fragmented due to the presence of various competitors operating in the production sector of treatments for swine respiratory illnesses. These businesses are pursuing strategies such as mergers and acquisitions, partnerships and collaborations, and the introduction of new products in order to satisfy the demand of their customers and increase the size of their existing customer base. The following are some examples of significant development strategies employed by industry firms operating in the market for treatments for respiratory disorders affecting pigs:

AROVYNTM (tulathromycin injection) and NUFLOR®-S (florfenicol injectable solution) are two broad-spectrum, prescription antibiotics that are used to treat the primary pathogens that are linked to swine respiratory disease (SRD). In March 2022, Merck Animal Health, which is also known as MSD Animal Health outside of the United States and Canada, announced that these two antibiotics had been approved by the United States Food and Drug Administration (FDA).

In September of 2021, Invetx and Boehringer Ingelheim made public their intention to work together on the research, development, and eventual sale of novel veterinary pharmaceuticals.

Key players operating in the swine respiratory disease treatment market include Zoetis, Inc. Merck Animal Health, Bayer AG, Boehringer Ingelheim Vetmedica, Inc., Elanco Animal Health, Virbac Group, Norbrook, CevaSanteAnimale, Vetoquinol, Bimeda holdings PLC, and Agrilabs, Inc.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Swine Respiratory Diseases Treatment market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report

Micro and macro environment factors that are currently influencing the Swine Respiratory Diseases Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Causative agent

Virus

Mycoplasma

Bacteria

Others

Treatment

Drugs

Antibiotic

Others

Vaccines

Analog

Others

Route Of Administration

Oral

Parenteral

Distribution Channel

Veterinary hospitals

Veterinary clinics

Pharmacies

Others

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of Covid-19 Segment (2020-2021; US$ Million )

Pre Covid-19 situation

Post Covid-19 situation

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Swine Respiratory Diseases Treatment market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Swine Respiratory Diseases Treatment market?

Which is the largest regional market for Swine Respiratory Diseases Treatment market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Swine Respiratory Diseases Treatment market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Swine Respiratory Diseases Treatment market worldwide?

Table of Contents

1. Preface

• 1.1. Report Description
  • 1.1.1. Purpose of the Report
  • 1.1.2. Target Audience
  • 1.1.3. Key Offerings
• 1.2. Market Segmentation
• 1.3. Research Methodology
  • 1.3.1. Phase I - Secondary Research
  • 1.3.2. Phase II - Primary Research
  • 1.3.3. Phase III - Expert Panel Review
  • 1.3.4. Assumptions
  • 1.3.5. Approach Adopted

2. Executive Summary

• 2.1. Market Snapshot: Global Swine Respiratory Diseases Treatment Market
• 2.2. Global Swine Respiratory Diseases Treatment Market, By Causative agent, 2021 (US$ Million)
• 2.3. Global Swine Respiratory Diseases Treatment Market, By Treatment, 2021 (US$ Million)
• 2.4. Global Swine Respiratory Diseases Treatment Market, By Route Of Administration, 2021 (US$ Million)
• 2.5. Global Swine Respiratory Diseases Treatment Market, By Distribution Channel, 2021 (US$ Million)
• 2.6. Global Swine Respiratory Diseases Treatment Market, By Geography, 2021 (US$ Million)
• 2.7. Attractive Investment Proposition by Geography, 2021

3. Swine Respiratory Diseases Treatment Market: Competitive Analysis

• 3.1. Market Positioning of Key Swine Respiratory Diseases Treatment Market Vendors
• 3.2. Strategies Adopted by Swine Respiratory Diseases Treatment Market Vendors
• 3.3. Key Industry Strategies
• 3.4. Tier Analysis 2021 Versus 2030

4. Swine Respiratory Diseases Treatment Market: Macro Analysis & Market Dynamics

• 4.1. Introduction
• 4.2. Global Swine Respiratory Diseases Treatment Market Value, 2020 - 2030, (US$ Million)
• 4.3. Market Dynamics
  • 4.3.1. Market Drivers
  • 4.3.2. Market Restraints
  • 4.3.3. Key Challenges
  • 4.3.4. Key Opportunities
• 4.4. Impact Analysis of Drivers and Restraints
• 4.5. See-Saw Analysis

5. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)

• 5.1. Market Overview
• 5.2. Growth & Revenue Analysis: 2021 Versus 2030
• 5.3. Market Segmentation
  • 5.3.1. Virus
  • 5.3.2. Mycoplasma
  • 5.3.3. Bacteria
  • 5.3.4. Others

6. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)

• 6.1. Market Overview
• 6.2. Growth & Revenue Analysis: 2021 Versus 2030
• 6.3. Market Segmentation
  • 6.3.1. Drugs
    • 6.3.1.1. Antibiotic
    • 6.3.1.2. Others
  • 6.3.2. Vaccines
  • 6.3.3. Analog
  • 6.3.4. Others

7. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)

• 7.1. Market Overview
• 7.2. Growth & Revenue Analysis: 2021 Versus 2030
• 7.3. Market Segmentation
  • 7.3.1. Oral
  • 7.3.2. Parenteral

8. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)

• 8.1. Market Overview
• 8.2. Growth & Revenue Analysis: 2021 Versus 2030
• 8.3. Market Segmentation
  • 8.3.1. Veterinary hospitals
  • 8.3.2. Veterinary clinics
  • 8.3.3. Pharmacies
  • 8.3.4. Others

9. North America Swine Respiratory Diseases Treatment Market, 2020-2030, USD (Million)

• 9.1. Market Overview
• 9.2. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
• 9.3. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
• 9.4. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
• 9.5. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
• 9.6.Swine Respiratory Diseases Treatment Market: By Region, 2020-2030, USD (Million)
  • 9.6.1.North America
    • 9.6.1.1. U.S.
      • 9.6.1.1.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 9.6.1.1.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 9.6.1.1.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 9.6.1.1.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
    • 9.6.1.2. Canada
      • 9.6.1.2.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 9.6.1.2.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 9.6.1.2.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 9.6.1.2.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
    • 9.6.1.3. Rest of North America
      • 9.6.1.3.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 9.6.1.3.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 9.6.1.3.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 9.6.1.3.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)

10. UK and European Union Swine Respiratory Diseases Treatment Market, 2020-2030, USD (Million)

• 10.1. Market Overview
• 10.2. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
• 10.3. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
• 10.4. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
• 10.5. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
• 10.6.Swine Respiratory Diseases Treatment Market: By Region, 2020-2030, USD (Million)
  • 10.6.1.UK and European Union
    • 10.6.1.1. UK
      • 10.6.1.1.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 10.6.1.1.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 10.6.1.1.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 10.6.1.1.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
    • 10.6.1.2. Germany
      • 10.6.1.2.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 10.6.1.2.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 10.6.1.2.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 10.6.1.2.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
    • 10.6.1.3. Spain
      • 10.6.1.3.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 10.6.1.3.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 10.6.1.3.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 10.6.1.3.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
    • 10.6.1.4. Italy
      • 10.6.1.4.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 10.6.1.4.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 10.6.1.4.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 10.6.1.4.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
    • 10.6.1.5. France
      • 10.6.1.5.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 10.6.1.5.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 10.6.1.5.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 10.6.1.5.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
    • 10.6.1.6. Rest of Europe
      • 10.6.1.6.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 10.6.1.6.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 10.6.1.6.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 10.6.1.6.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)

11. Asia Pacific Swine Respiratory Diseases Treatment Market, 2020-2030, USD (Million)

• 11.1. Market Overview
• 11.2. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
• 11.3. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
• 11.4. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
• 11.5. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
• 11.6.Swine Respiratory Diseases Treatment Market: By Region, 2020-2030, USD (Million)
  • 11.6.1.Asia Pacific
    • 11.6.1.1. China
      • 11.6.1.1.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 11.6.1.1.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 11.6.1.1.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 11.6.1.1.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
    • 11.6.1.2. Japan
      • 11.6.1.2.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 11.6.1.2.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 11.6.1.2.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 11.6.1.2.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
    • 11.6.1.3. India
      • 11.6.1.3.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 11.6.1.3.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 11.6.1.3.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 11.6.1.3.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
    • 11.6.1.4. Australia
      • 11.6.1.4.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 11.6.1.4.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 11.6.1.4.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 11.6.1.4.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
    • 11.6.1.5. South Korea
      • 11.6.1.5.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 11.6.1.5.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 11.6.1.5.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 11.6.1.5.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
    • 11.6.1.6. Rest of Asia Pacific
      • 11.6.1.6.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 11.6.1.6.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 11.6.1.6.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 11.6.1.6.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)

12. Latin America Swine Respiratory Diseases Treatment Market, 2020-2030, USD (Million)

• 12.1. Market Overview
• 12.2. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
• 12.3. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
• 12.4. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
• 12.5. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
• 12.6.Swine Respiratory Diseases Treatment Market: By Region, 2020-2030, USD (Million)
  • 12.6.1.Latin America
    • 12.6.1.1. Brazil
      • 12.6.1.1.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 12.6.1.1.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 12.6.1.1.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 12.6.1.1.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
    • 12.6.1.2. Mexico
      • 12.6.1.2.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 12.6.1.2.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 12.6.1.2.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 12.6.1.2.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
    • 12.6.1.3. Rest of Latin America
      • 12.6.1.3.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 12.6.1.3.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 12.6.1.3.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 12.6.1.3.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)

13. Middle East and Africa Swine Respiratory Diseases Treatment Market, 2020-2030, USD (Million)

• 13.1. Market Overview
• 13.2. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
• 13.3. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
• 13.4. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
• 13.5. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
• 13.6.Swine Respiratory Diseases Treatment Market: By Region, 2020-2030, USD (Million)
  • 13.6.1.Middle East and Africa
    • 13.6.1.1. GCC
      • 13.6.1.1.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 13.6.1.1.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 13.6.1.1.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 13.6.1.1.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
    • 13.6.1.2. Africa
      • 13.6.1.2.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 13.6.1.2.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 13.6.1.2.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 13.6.1.2.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)
    • 13.6.1.3. Rest of Middle East and Africa
      • 13.6.1.3.1. Swine Respiratory Diseases Treatment Market: By Causative agent, 2020-2030, USD (Million)
      • 13.6.1.3.1. Swine Respiratory Diseases Treatment Market: By Treatment, 2020-2030, USD (Million)
      • 13.6.1.3.1. Swine Respiratory Diseases Treatment Market: By Route Of Administration, 2020-2030, USD (Million)
      • 13.6.1.3.1. Swine Respiratory Diseases Treatment Market: By Distribution Channel, 2020-2030, USD (Million)

14. Company Profile

• 14.1. Zoetis, Inc.
  • 14.1.1. Company Overview
  • 14.1.2. Financial Performance
  • 14.1.3. Product Portfolio
  • 14.1.4. Strategic Initiatives
• 14.2. Merck Animal Health
  • 14.2.1. Company Overview
  • 14.2.2. Financial Performance
  • 14.2.3. Product Portfolio
  • 14.2.4. Strategic Initiatives
• 14.3. Bayer AG
  • 14.3.1. Company Overview
  • 14.3.2. Financial Performance
  • 14.3.3. Product Portfolio
  • 14.3.4. Strategic Initiatives
• 14.4. Boehringer Ingelheim Vetmedica, Inc.
  • 14.4.1. Company Overview
  • 14.4.2. Financial Performance
  • 14.4.3. Product Portfolio
  • 14.4.4. Strategic Initiatives
• 14.5. Elanco Animal Health
  • 14.5.1. Company Overview
  • 14.5.2. Financial Performance
  • 14.5.3. Product Portfolio
  • 14.5.4. Strategic Initiatives
• 14.6. Virbac Group
  • 14.6.1. Company Overview
  • 14.6.2. Financial Performance
  • 14.6.3. Product Portfolio
  • 14.6.4. Strategic Initiatives
• 14.7. Norbrook
  • 14.7.1. Company Overview
  • 14.7.2. Financial Performance
  • 14.7.3. Product Portfolio
  • 14.7.4. Strategic Initiatives
• 14.8. CevaSanteAnimale
  • 14.8.1. Company Overview
  • 14.8.2. Financial Performance
  • 14.8.3. Product Portfolio
  • 14.8.4. Strategic Initiatives
• 14.9. Vetoquinol
  • 14.9.1. Company Overview
  • 14.9.2. Financial Performance
  • 14.9.3. Product Portfolio
  • 14.9.4. Strategic Initiatives
• 14.10. Bimeda holdings PLC
  • 14.10.1. Company Overview
  • 14.10.2. Financial Performance
  • 14.10.3. Product Portfolio
  • 14.10.4. Strategic Initiatives
• 14.11. Agrilabs, Inc.
  • 14.11.1. Company Overview
  • 14.11.2. Financial Performance
  • 14.11.3. Product Portfolio
  • 14.11.4. Strategic Initiatives